Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
18.59
-0.06 (-0.32%)
At close: Oct 31, 2024, 4:00 PM
18.60
+0.01 (0.05%)
After-hours: Oct 31, 2024, 6:06 PM EDT
Summit Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Summit Therapeutics stock have an average target of 35.67, with a low estimate of 23 and a high estimate of 44. The average target predicts an increase of 91.88% from the current stock price of 18.59.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SMMT stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $45 → $44 | Strong Buy | Maintains | $45 → $44 | +136.69% | Oct 31, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +142.07% | Oct 4, 2024 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $19 → $23 | Strong Buy → Hold | Downgrades | $19 → $23 | +23.72% | Sep 27, 2024 |
| Stifel | Stifel | Strong Buy Maintains $25 → $40 | Strong Buy | Maintains | $25 → $40 | +115.17% | Sep 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +142.07% | Sep 17, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.28
from -0.99
EPS Next Year
-0.29
from -0.28
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 15.9M | ||
| Avg | n/a | n/a | 12.8M | ||
| Low | n/a | n/a | 9.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.27 | -0.27 | -0.33 | ||
| Avg | -0.28 | -0.29 | -0.38 | ||
| Low | -0.28 | -0.30 | -0.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.